SRPT Stock Sarepta Therapeutics, Inc.
ACCUMULATE US · NasdaqGSControversial but liquid name with major catalyst optionality and high beta upside.
Future value: $21.64 (+20.34%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Large catalyst potential, but risk profile remains elevated.
- ▾Below 50-day MA (-6.47%)
- ▸~20% upside to price target
Is SRPT a buy right now?
Trend: SRPT is trading below the 50-day average (-6.45%), RSI 48 — neutral momentum, with a 3-month return of +16.53%.
Valuation & quality: Sarepta Therapeutics, Inc. trades on forward P/E 7.3, PEG -0.09, price-to-book 1.24; fundamentals show net margin -6.9%, return on equity -9.5%, revenue growth -34.3% year on year.
Analyst consensus: 22 analysts have a mean 12-month price target of $21.64 (+20.3% vs the last close; range $5.00 – $38.00), consensus rating “hold”.
Our screen: ACCUMULATE (score 1) — Controversial but liquid name with major catalyst optionality and high beta upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +29.80% | -4.00% | -14.40% | +0.60% | -17.30% | +41.50% | -13.40% | -1.30% |
Fundamentals
Analyst price target
Technical signals
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Sector: Healthcare · Industry: Biotechnology · United States · 835 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.